Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Quality Lowdown: CMC Challenges Include Pfizer Unit's Quest For Injectable Acetaminophen

May 09 2023

• By Bowman Cox

The Quality Lowdown — a lowdown on cmc reviews

Related Content

Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays

Jul 23 2021

Hikma Should Revisit Investigations, FDA Warning Letter Says

Nov 05 2014

More Options For Opioid Overdose: Nasal Naloxone On Brink Of OTC Use, While Opiant And Orexo Stay Rx To Counter High-Potency Opioids

Feb 16 2023

Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections

Mar 23 2023

Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response

Mar 23 2023

Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza

Mar 26 2023

FY 2015 Drug GMP Warning Letters Hit Compounders and Foreign Sites

Jan 29 2016

Related Companies

InnoPharma Inc.

Pfizer Inc.

Hikma Pharmaceuticals plc

Azurity Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

Incyte Corporation

Cidara Therapeutics, Inc.

Thermo Fisher Scientific

Pharming Group N.V.

Novartis AG

SkyePharma PLC

Additional Topics

United States Manufacturing Quality Drug Approval Standards Compliance BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window